AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11489017 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Number of subjects: 0
Study 9781832 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 39000
Study 9781832 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 39000
Study 7840507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen 20 mg once daily for two years
Number of subjects: 128
Study 7840507 — intervention group
Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 128
Study 2849717 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (500 mg/m² IV every 8 hours for 7 days, followed by 800 mg orally four times daily for 30 days)
Number of subjects: 27
Study 2849717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous placebo for 7 days, followed by oral placebo for 30 days)
Number of subjects: 27
Study 2849717 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir and Placebo
Number of subjects: 27
Study 1498372 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical khellin (2% solution in acetone and propylene glycol) plus sunlight exposure for 4 months with 3 weekly applications and exposure times up to 90 min.
Number of subjects: 41
Study 1498372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (acetone and propylene glycol) plus sunlight exposure for 4 months with 3 weekly applications and exposure times up to 90 min.
Number of subjects: 41
Study 902597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (3 X 5000 IU/24 h)
Number of subjects: 30
Study 902597 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (3.6 g daily)
Number of subjects: 30
Study 30324251 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodegenerative diseases
Number of subjects: 96
Study 30324251 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-induced movement disorders
Number of subjects: 96
Study 30324251 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional movement disorders
Number of subjects: 96
Study 30324251 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural brain lesions
Number of subjects: 96
Study 28653221 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice alert intervention
Number of subjects: 12981
Study 28653221 — intervention group
Group type: COMPARATOR
Intervention: Comparator (no alert)
Number of subjects: 12981
Study 24911356 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump-landing prevention program (3 months, coach-supervised)
Number of subjects: 116
Study 24911356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 116
Study 23369180 — intervention group
Group type: EXPERIMENTAL
Intervention: Task complexity (simple/complex)
Number of subjects: 120
Study 23369180 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy beliefs
Number of subjects: 120
Study 23369180 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior knowledge of English vocabulary
Number of subjects: 120
Study 21844490 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring and study physician medication management
Number of subjects: 296
Study 19858751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast movements with accommodated resistance (FACC)
Number of subjects: 48
Study 19858751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter resistance and fast movement (Fast)
Number of subjects: 48
Study 19858751 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance/slow movement (Slow)
Number of subjects: 48
Study 19858751 — intervention group
Group type: EXPERIMENTAL
Intervention: FACC
Number of subjects: 48
Study 19858751 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow
Number of subjects: 48
Study 19858751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast
Number of subjects: 48
Study 17142931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 0
Study 16225573 — intervention group
Group type: EXPERIMENTAL
Intervention: ESSURE
Number of subjects: 89
Study 16225573 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sterilisation
Number of subjects: 89
Study 11426167 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency medial branch neurotomy
Number of subjects: 60
Study 9635648 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group (DO2 > or =600 mL/min/m2)
Number of subjects: 105
Study 9635648 — intervention group
Group type: COMPARATOR
Intervention: Control group (DO2 450 to 550 mL/min/m2)
Number of subjects: 105
Study 9635648 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >75 yrs group
Number of subjects: 105
Study 8071011 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting accrual performance in cancer control protocols
Number of subjects: 52
Study 3341317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (975 mg/d)
Number of subjects: 14
Study 3341317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31918406 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 430
Study 31918406 — intervention group
Group type: COMPARATOR
Intervention: Sedentary behavior
Number of subjects: 430
Study 31918406 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity (LPA)
Number of subjects: 430
Study 31918406 — intervention group
Group type: COMPARATOR
Intervention: Sleep
Number of subjects: 430
Study 30305153 — intervention group
Group type: EXPERIMENTAL
Intervention: DESCANT intervention
Number of subjects: 360
Study 30305153 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 360
Study 28483653 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 119
Study 28483653 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 119
Study 25453582 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/GSD patch
Number of subjects: 398
Study 25453582 — intervention group
Group type: COMPARATOR
Intervention: EE/NGMN patch
Number of subjects: 398
Study 23578862 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia (45-50 vol%)
Number of subjects: 30
Study 23578862 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia (1-1.4 vol%)
Number of subjects: 30
Study 21798642 — intervention group
Group type: EXPERIMENTAL
Intervention: USB-PRP combination
Number of subjects: 10
Study 21798642 — intervention group
Group type: COMPARATOR
Intervention: USB alone (control)
Number of subjects: 10
Study 19125141 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute interactive, computerized condom use intervention
Number of subjects: 430
Study 19125141 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (15-minute computerized multiple health risk assessment with no intervention)
Number of subjects: 430
Study 16959690 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivostat patient-derived fibrin sealant
Number of subjects: 80
Study 16959690 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional hemostatic treatment)
Number of subjects: 80
Study 14593457 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP delivered by helmet
Number of subjects: 17
Study 14593457 — intervention group
Group type: COMPARATOR
Intervention: nCPAP delivered by face mask (control)
Number of subjects: 17
Study 11403353 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mmol/day sodium chloride supplementation
Number of subjects: 46
Study 11403353 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mmol/day sodium chloride supplementation
Number of subjects: 46
Study 11403353 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mmol/day sodium chloride supplementation
Number of subjects: 46
Study 11403353 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mmol/day sodium chloride supplementation
Number of subjects: 46
Study 11403353 — intervention group
Group type: EXPERIMENTAL
Intervention: AGT genotype modulation
Number of subjects: 46
Study 9590488 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute step test
Number of subjects: 85
Study 9590488 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walking test
Number of subjects: 85
Study 7871114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheehan's Patient‐Rated Anxiety Scale
Number of subjects: 87
Study 7871114 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck's Cognition Checklist
Number of subjects: 87
Study 3139428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg sublingual nitroglycerin (Nitromex)
Number of subjects: 9
Study 3139428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg sublingual nitroglycerin (Nitromex)
Number of subjects: 9
Study 3139428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg sublingual nitroglycerin (Nitromex)
Number of subjects: 9
Study 3139428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual nitroglycerin (Nitromex)
Number of subjects: 9
Study 3139428 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg ordinary nitroglycerin
Number of subjects: 9
Study 3139428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31387119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fish oil (LFO) group (20% LC n‐3 PUFAs, 0.5 g/d)
Number of subjects: 5531
Study 31387119 — intervention group
Group type: EXPERIMENTAL
Intervention: High fish oil (HFO) group (60% LC n‐3 PUFAs, 2.0 g/d)
Number of subjects: 5531
Study 31387119 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group (0% LC n‐3 PUFAs, 0 g/d)
Number of subjects: 5531
Study 31387119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fish oil (LFO) group
Number of subjects: 5531
Study 31387119 — intervention group
Group type: EXPERIMENTAL
Intervention: High fish oil (HFO) group
Number of subjects: 5531
Study 27225617 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of 50,000 IU vitamin D3 every week for 8 weeks, followed by 1 pearl every 2 weeks for 4 weeks (total of 3 months)
Number of subjects: 40
Study 27225617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D treatment)
Number of subjects: 40
Study 25438724 — intervention group
Group type: EXPERIMENTAL
Intervention: Encenicline 1 mg oral capsule
Number of subjects: 0
Study 25438724 — intervention group
Group type: EXPERIMENTAL
Intervention: Encenicline 1 mg oral solution
Number of subjects: 0
Study 25438724 — intervention group
Group type: EXPERIMENTAL
Intervention: Encenicline 20 mg dose
Number of subjects: 0
Study 25438724 — intervention group
Group type: EXPERIMENTAL
Intervention: Encenicline 1-180 mg doses
Number of subjects: 0
Study 25438724 — intervention group
Group type: EXPERIMENTAL
Intervention: Encenicline (various doses)
Number of subjects: 0
Study 25438724 — intervention group
Group type: EXPERIMENTAL
Intervention: Encenicline (1-180 mg)
Number of subjects: 0
Study 23883525 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program (intensive exercises in the ICU and the ward and as outpatients)
Number of subjects: 150
Study 23883525 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 21704313 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous E(2) (100 μg/24 h) during 2 weeks perimenstrually
Number of subjects: 27
Study 21704313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 19321996 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of prostate (HoLEP)
Number of subjects: 30
Study 19321996 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 30
Study 17039221 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 26
Study 17039221 — intervention group
Group type: COMPARATOR
Intervention: Qigong
Number of subjects: 26
Study 15112179 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxercalciferol treatment
Number of subjects: 55
Study 15112179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 15112179 — intervention group
Group type: COMPARATOR
Intervention: Doxercalciferol treatment and Placebo
Number of subjects: 55
Study 10778998 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment with ticlopidine (Group B)
Number of subjects: 404
Study 10778998 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant treatment with acenocoumarol (Group A)
Number of subjects: 404
Study 9323513 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa treatment (ON)
Number of subjects: 15
Study 9323513 — intervention group
Group type: COMPARATOR
Intervention: OFF L-Dopa
Number of subjects: 15
Study 1610044 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg pseudoephedrine
Number of subjects: 120
Study 1610044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3884576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 0
Study 31080168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 8 weeks for 52 weeks, after 5 initial doses every 4 weeks.
Number of subjects: 553
Study 30284557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral edoxaban
Number of subjects: 1050
Study 30284557 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous dalteparin
Number of subjects: 1050
Study 30284557 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1050
Study 30284557 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous dalteparin (in Select-D study)
Number of subjects: 1050
Study 25960146 — intervention group
Group type: EXPERIMENTAL
Intervention: LA Sprouts intervention
Number of subjects: 319
Study 25960146 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 319
Study 23807272 — intervention group
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV‐1 gag/pol/nef vaccine
Number of subjects: 1134
Study 23807272 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk behaviors (crack cocaine use, unprotected anal sex, drug use)
Number of subjects: 1134
Study 23807272 — intervention group
Group type: EXPERIMENTAL
Intervention: Study enrollment
Number of subjects: 1134
Study 23807272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsterilized women
Number of subjects: 1134
Study 22112610 — intervention group
Group type: EXPERIMENTAL
Intervention: C421A variant (CA+AA versus CC) in ABCG2
Number of subjects: 511
Study 22112610 — intervention group
Group type: EXPERIMENTAL
Intervention: C421A variant in ABCG2
Number of subjects: 511
Study 22112610 — intervention group
Group type: COMPARATOR
Intervention: Other variants in ABCB1 or ABCC2
Number of subjects: 511
Study 19243824 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 810
Study 17480139 — intervention group
Group type: EXPERIMENTAL
Intervention: Quyu Xiaoban capsules (QYXB) plus aspirin (300 mg loading dose, 100 mg maintenance dose) for 4 weeks
Number of subjects: 90
Study 17480139 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg loading dose, 100 mg maintenance dose) for 4 weeks
Number of subjects: 90
Study 15228130 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5%/clindamycin 1% gel (BP/C)
Number of subjects: 88
Study 15228130 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 88
Study 11754710 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib, 25 mg/d
Number of subjects: 382
Study 11754710 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib, 12.5 mg/d
Number of subjects: 382
Study 11754710 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib, 200 mg/d
Number of subjects: 382
Study 11754710 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen, 4000 mg/d
Number of subjects: 382
Study 9475649 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (3-4 times per week for 30 min at 60% peak heart rate for 12 weeks, then 40-50 min at 75% peak heart rate for 12 weeks)
Number of subjects: 17
Study 9475649 — intervention group
Group type: COMPARATOR
Intervention: Control group (yoga exercises over the same time period)
Number of subjects: 17
Study 10609129 — intervention group
Group type: EXPERIMENTAL
Intervention: Current clinical protocols with in-hospital observation and discharge after several hours/days
Number of subjects: 558
Study 10609129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine-atropine stress echocardiography performed between 0 and 18 hours after randomization
Number of subjects: 558
Study 10609129 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic exercise stress test performed between 0 and 18 hours after randomization
Number of subjects: 558
Study 2069792 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 2069792 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 6658629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 g intramuscularly)
Number of subjects: 406
Study 6658629 — intervention group
Group type: COMPARATOR
Intervention: Penicillin (4.8 X 10(6) units aqueous procaine penicillin G intramuscularly)
Number of subjects: 406
Study 6658629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 406
Study 6658629 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 406
Study 30211725 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 126
Study 30211725 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 126
Study 28933186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol media literacy (AML) intervention
Number of subjects: 165
Study 28933186 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 165
Study 28933186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 165
Study 26851469 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoured foam
Number of subjects: 21
Study 26851469 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight foam
Number of subjects: 21
Study 26851469 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood
Number of subjects: 21
Study 26851469 — intervention group
Group type: EXPERIMENTAL
Intervention: General ICM measurement
Number of subjects: 21
Study 24249309 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (PostC) during primary PCI
Number of subjects: 62
Study 22784040 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-FTC (tenofovir disoproxil fumarate and emtricitabine)
Number of subjects: 2120
Study 22784040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2120
Study 22784040 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-FTC
Number of subjects: 2120
Study 20383644 — intervention group
Group type: EXPERIMENTAL
Intervention: R (Strength training)
Number of subjects: 56
Study 20383644 — intervention group
Group type: EXPERIMENTAL
Intervention: E (Endurance training)
Number of subjects: 56
Study 20383644 — intervention group
Group type: EXPERIMENTAL
Intervention: CB (Combined training)
Number of subjects: 56
Study 18175765 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic index measurement of cheese-puffs
Number of subjects: 311
Study 18175765 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic index measurement of fruit-leather
Number of subjects: 311
Study 18175765 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-individual variation (refCV) for repeated reference food tests
Number of subjects: 311
Study 18175765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean laboratory GI
Number of subjects: 311
Study 18175765 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-laboratory SD of GI
Number of subjects: 311
Study 15910834 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol ointment applied at the surgical site at the end of procedure and 3rd day postoperatively
Number of subjects: 100
Study 15910834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chloramphenicol ointment)
Number of subjects: 100
Study 12795548 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood induction (listening to classical music for 8 min)
Number of subjects: 75
Study 12795548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood induction (listening to classical music for 8 min)
Number of subjects: 75
Study 12795548 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 75
Study 10221231 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel 75 micrograms
Number of subjects: 71
Study 10221231 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel 30 micrograms
Number of subjects: 71
Study 7977145 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk chocolate (280 g/d or 10 oz/d)
Number of subjects: 0
Study 7977145 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk chocolate (46.2 g or 1.65 oz)
Number of subjects: 0
Study 7977145 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic substitution of one milk chocolate bar per day for a high-carbohydrate snack
Number of subjects: 0
Study 2566781 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered blood (using 'Imugard IG500' filters)
Number of subjects: 72
Study 2566781 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered blood
Number of subjects: 72
Study 2566781 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered blood (in very low birthweight infants)
Number of subjects: 72
Study 2566781 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered blood (in very low birthweight infants)
Number of subjects: 72
Study 165862 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral red photodynamic inactivation treatment
Number of subjects: 19
Study 165862 — intervention group
Group type: COMPARATOR
Intervention: Phenol red (control)
Number of subjects: 19
Study 30689757 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 7766
Study 30689757 — intervention group
Group type: COMPARATOR
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 7766
Study 29142090 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality rehabilitation training (VR)
Number of subjects: 120
Study 29142090 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 120